Aside from the fact that the poster,"Norisk....." has decided to flood the airways with his supposed analytical expertise, based on what credentials we do not know, I believe the 10Q is fairly straight forward in explaining that increases in expenses in Q2 are related to a "full court press" on filing the BLA(marketing license application) in the UK, nearly doubling from a year ago!!! That indicates that the approval process in the UK is "Top Priority", which it should be. People 11111, that's the key that opens the revenue streams that actually improve shareholder values unlike the JA that is a known road block thrown up by our competitors to try to delay approvals. You do realize that the UK MHRA could care less about the JA !!!! How does a JA save lives??? The only lives saved by waiting for a JA is the lives of the naked short sellers supported by those that are endeavoring to bankrupt the company. AND unfortunately, the US regulatory process supports those trying to delay the approvals as pointed out by Dr. Ashkan in his quote at ASCO,"The US FDA is so deep into political and financial considerations that they no longer have the patients best interests at heart"!!!!
So let's look at this important section of the 10Q:
For the three months ended June 30, 2022 and 2021, research and development expense was $13.6 million and $5.5 million, respectively. The increase was mainly related to SOW 6 that was entered into in April, 2022 for five workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for drafting of key portions of the application and for three required licenses for the
23
Table of Contents
Sawston facility. During the three months ended June 30, 2022, the Company expensed $3.8 million for cash milestones (but only paid $0.5 million) and $5.3 million for stock-based milestones that the Company believes are probable to be achieved and hence to become payable during the contract period. The $5.3 million stock-based compensation expense, for the milestones, were offset by a decrease of $1.9 million of stock-based compensation in research and development which was related to cancellation of certain unvested performance-based awards and less amortization related to previously granted awards.
Costs related to UK approvals were up 247% in Q2 , 2022 from Q2, 2021!! What the hell does that tell you?? YES, we're within days, minutes, hours of finalizing and filing the BLA with the UK, MHRA. And when filed, it will be approved and that's the end of the forces that have tried to bankrupt Northwest and cover their naked short positions!!! That's the truth people and everyone on both sides of te battle know it only too well !!!
So take a deep breath, relax and enjoy the moments before those that have mercilessly tried to deny suffering cancer patients access to the DCVax Complex and hope for a longer life go down in flames!!! I don't know about you, but personally, I'd pay a million to get to see the look on te faces of the AF's of the world as they realize defeat.!!!!!
Cheers,
BB
AI
